In-depth trading ideas

Discover detailed market analysis from traders. See how others approach this instrument, compare different strategies, and discover perspectives that can shape your own view.

RAPP: $82 Analyst Target — Can Buyers Defend This Demand Zone ?RAPP is testing the $23.49–$26.31 confluence zone, where demand overlaps with the Volume Profile POC. 📊 Quant context: 8.2M shares traded on Oct. 20 — approximately 16× the reported average volume. −14.7% closing move on Oct. 21, despite Jones Trading raising its target from $50 to $82. Phase 2 results: RAP-219 achieved a 3.1-point placebo-adjusted improvement in YMRS at Week 3 (p = 0.045; n = 253). Price is now roughly 50% below its 52-week high. Will buyers defend this zone and trigger a

by InstitutionalTradingResearch

Rapport Therapeutics, Inc. (RAPP) Targets Neurological Disorders Rapport Therapeutics, Inc. (RAPP) is a clinical-stage biotech focused on neuroscience, developing small-molecule therapies for conditions like epilepsy and other brain disorders. The company grows by advancing its pipeline, leveraging novel targets, and addressing large unmet needs in neurological care where current treatments often fall short. On the chart, RAPP printed a confirmation bar with increasing volume as price moved above the .236 Fibonacci level and into the momentum zone. A trailin

by traderspro_charts

Small, quick trades get a bad rap - this one is a good RAPP.This is a newer system I've been using for about a week now, though I've backtested it on almost 3000 trades at this point and it's done magnificently. I use proprietary indicators for both signals and price targets, but the blue arrows on the chart show what the signals have generated since October. The arrows indicate entries and exits, and you can see that only once has this not paid in the same trading day as entry. The thing I like most is the stretch of no entries from Mid-December to

by redwingcoach